mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open

By Jardine Meg J.   Liyanage Thaminda   Buxton Erin   Perkovic Vlado  

Nephrology Dialysis Transplantation, Vol. 28, Iss. 2, 2013-02 ,pp. : 242-244

Oxford University Press

Access to resources Recommend Favorite

Nephrotic syndrome and autosomal dominant polycystic kidney disease

By Visciano Bianca   Di Pietro Renata A.   Rossano Roberta   Mancini Antonio   Zamboli Pasquale   Cianciaruso Bruno   Pisani Antonio  

Clinical Kidney Journal, Vol. 5, Iss. 6, 2012-12 ,pp. : 508-511

Oxford University Press

Access to resources Recommend Favorite

Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study

By Stallone Giovanni   Grandaliano Giuseppe   Bristogiannis Christos   Macarini Luca   Mezzopane Daniela   Bruno Francesca   Montemurno Eustacchio   Schirinzi Annalisa   Sabbatini Massimo   Pisani Antonio   Tataranni Tiziana   Schena Francesco Paolo   Gesualdo Loreto  

Nephrology Dialysis Transplantation, Vol. 27, Iss. 9, 2012-09 ,pp. : 3560-3567

Oxford University Press

Access to resources Recommend Favorite

Peritransplant management of retained native kidneys in autosomal dominant polycystic kidney disease

By Bennett William M.  

Nephrology Dialysis Transplantation, Vol. 28, Iss. 2, 2013-02 ,pp. : 245-246

Oxford University Press

Access to resources Recommend Favorite

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease

By Helal Imed   McFann Kim   Reed Berenice   Yan Xiang-Dong   Schrier Robert W.   Fick-Brosnahan Godela M.  

Nephrology Dialysis Transplantation, Vol. 28, Iss. 2, 2013-02 ,pp. : 380-385

Oxford University Press

Access to resources Recommend Favorite